Company research
Maze Therapeutics, Inc.
CIK 1842295Updated Sep 26, 2026
SecurityMAZE · NASDAQ · equity
MAZE price & chart
Loading TradingView…
NASDAQ:MAZE on TradingView ↗About the company
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.
In the news
Maze Therapeutics Announces $150 Million Registered Offering ↗
Recent filings
4 filing
4 filing
3 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 397,127,000Source | 240,542,000Source |
| Property, Plant and Equipment, NetUSD | 5,044,000Source | 6,668,000Source |
| Current assets: | ||
| Cash and Cash Equivalents, at Carrying ValueUSD | 189,247,000Source | 196,812,000Source |
| Assets, CurrentUSD | 349,717,000Source | 201,671,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,800,000Source | 4,859,000Source |
| Operating Lease, Right-of-Use AssetUSD | 20,116,000Source | 23,250,000Source |
| Other Assets, NoncurrentUSD | 3,048,000Source | 7,865,000Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 42,161,000Source | 43,638,000Source |
| Stockholders’ equity: | ||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 49,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 844,354,000Source | 47,242,000Source |
| Retained Earnings (Accumulated Deficit)USD | -489,547,000Source | -358,427,000Source |
| Stockholders' Equity Attributable to ParentUSD | 354,966,000Source | -311,183,000Source |
| Liabilities and EquityUSD | 397,127,000Source | 240,542,000Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 22,556,000Source | 20,673,000Source |
| Operating Lease, Liability, CurrentUSD | 4,795,000Source | 4,632,000Source |
| Accounts Payable, CurrentUSD | 1,794,000Source | 1,939,000Source |
| Operating Lease, Liability, NoncurrentUSD | 18,511,000Source | 21,996,000Source |
| Other Liabilities, NoncurrentUSD | 1,094,000Source | 969,000Source |
| Additional Financial Items | ||
| AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD | 110,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -131,120,000Source | 52,231,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 16,400,000Source | 9,646,000Source |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts PayableUSD | -27,000Source | -204,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -111,940,000Source | 75,954,000Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -170,962,000Source | -1,147,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 794,000Source | 1,147,000Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 275,337,000Source | 92,847,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 190,335,000Source | 197,900,000Source |
| Supplemental disclosure of cash flow information: | ||
| Income Taxes Paid, NetUSD | — | 1,230,000Source |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 16,400,000Source | 9,646,000Source |
| DepreciationUSD | 2,403,000Source | 3,297,000Source |
| General and Administrative ExpenseUSD | 34,451,000Source | 26,418,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 1,172,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | 110,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -131,120,000Source | 52,231,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -131,120,000Source | 3,405,000Source |
| Operating ExpensesUSD | 142,899,000Source | 109,914,000Source |
| Operating Lease, ExpenseUSD | 3,134,000Source | 2,889,000Source |
| Proceeds from Stock Options ExercisedUSD | 5,561,000Source | 733,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Total RevenueUSD | — | 167,500,000Source |
| Operating Income (Loss)USD | -142,899,000Source | 57,586,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -131,120,000Source | 53,403,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 1,172,000Source |
| Net Income (Loss) Attributable to ParentUSD | -131,120,000Source | 52,231,000Source |
| Earnings Per Share, BasicUSD per share | -3.05Source | 1.42Source |
| Earnings Per Share, DilutedUSD per share | -3.05Source | 1.25Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 42,976,024Source | 2,396,094Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 42,976,024Source | 2,730,299Source |
| Additional Financial Items | ||
| General and Administrative ExpenseUSD | 34,451,000Source | 26,418,000Source |
| Interest and Other IncomeUSD | 11,779,000Source | 4,654,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -131,120,000Source | 3,405,000Source |
| Operating ExpensesUSD | 142,899,000Source | 109,914,000Source |
| Operating Lease, ExpenseUSD | 3,134,000Source | 2,889,000Source |
| Research and Development ExpenseUSD | 108,448,000Source | 83,496,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | -33,854,000Source |
Filing attachments
d135740dex991.htm · 8-K · 2026-08-17
EX-99.1 2 d135740dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Maze Therapeutics Announces Appointments to Its Board of Directors August 13, 2026 Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm. D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precis…
Read attachment ↗maze-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 maze-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 Phase 2 trial of MZE782 in CKD on track for H1 2027 initiation Strong balance sheet with $495 million in cash, cash equivalents and m…
Read attachment ↗maze-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 maze-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027 Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD on track to initiate in 2026 Strong balance sheet with $528 m…
Read attachment ↗d115741dex41.htm · 8-K · 2026-04-22
EX-4.1 3 d115741dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: April [ ], 2026 ───────────────────────────────────────────────────────────── Maze Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns …
Read attachment ↗d115741dex991.htm · 8-K · 2026-04-22
EX-99.1 5 d115741dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Maze Therapeutics Announces $150 Million Registered Offering SOUTH SAN FRANCISCO, April 21, 2026 - Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common…
Read attachment ↗maze-ex99_1.htm · 8-K · 2026-03-25
EX-99.1 2 maze-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026 I…
Read attachment ↗